Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Jun. 2026,
Fulgent Genetics paid$24.1 Mil more to buy back shares than it received from issuing new shares.
It spent$0.1 Mil paying down its debt.
It paid$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received$0.0 Mil from paying cash dividends to shareholders.
It received$0.0 Mil on other financial activities.
In all, Fulgent Geneticsspent$24.2 Mil on financial activities for the
three
months ended in Jun. 2026.
Fulgent Genetics (NAS:FLGT) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Fulgent Genetics's issuance of stock for the
three
months ended in Jun. 2026 was $0.0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Fulgent Genetics's repurchase of stock for the
three
months ended in Jun. 2026 was $-24.1 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Fulgent Genetics's net issuance of debt for the
three
months ended in Jun. 2026 was $-0.1 Mil.
Fulgent Genetics spent$0.1 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Fulgent Genetics's net issuance of preferred for the
three
months ended in Jun. 2026 was $0.0 Mil.
Fulgent Genetics paid$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Fulgent Genetics's cash flow for dividends for the
three
months ended in Jun. 2026 was $0.0 Mil.
Fulgent Genetics received$0.0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Fulgent Genetics's other financing for the
three
months ended in Jun. 2026 was $0.0 Mil.
Fulgent Genetics received$0.0 Mil on other financial activities.
Fulgent Genetics Cash Flow from Financing Related Terms
Fulgent Genetics Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Fulgent Genetics's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulgent Genetics Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Fulgent Genetics's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-70.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of $-70.0 Mil mean?
Fulgent Genetics (FLGT) has a Cash Flow from Financing of $-70.0 Mil as of Jun. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Fulgent Genetics and its competitors.
Is Fulgent Genetics' Cash Flow from Financing too high?
Fulgent Genetics' current Cash Flow from Financing is $-70.0 Mil. Overall, Fulgent Genetics has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Cash Flow from Financing compare to MYGN and CSTL?
Fulgent Genetics' Cash Flow from Financing of $-70.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Diagnostics & Research company?
A good Cash Flow from Financing depends on the Medical Diagnostics & Research industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Fulgent Genetics and its competitors. Fulgent Genetics's current Cash Flow from Financing is $-70.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (FLGT) is currently considered Modestly Undervalued. The stock's GF Value™ is $24.36, compared to a current price of $18.55 — trading 23.9% below its estimated fair value. The current Cash Flow from Financing is $-70.0 Mil. Fulgent Genetics' overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Fulgent Genetics (FLGT), the current Cash Flow from Financing is $-70.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulgent Genetics (FLGT) Overvalued in 2026?
Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued.
The current stock price of $18.55 is trading 23.9% below its estimated GF Value™ of $24.36.
GuruFocus considers Fulgent Genetics to be Modestly Undervalued.
Key valuation signals for FLGT:
Cash Flow from Financing: $-70.0 Mil
GF Value™: $24.36 vs. price of $18.55 (23.9% below fair value)
No single metric tells the full story. See the FLGT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
65GF Score
Get the complete analysis for FLGT
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FLGT has been successfully added to your 
